A new treatment option for lung fibrosis is being developed by Purdue University scientists. Lung fibrosis has been a concern for COVID-19 patients. People with idiopathic pulmonary fibrosis (IPF) have a life expectancy of fewer than five years. Fibrotic diseases cause organ failure that leads to a